OOTR-N016 Trial Results to be Presented at SABCS 2022

The results of the OOTR-N016/KBCRN-B-003/PAB-HT trial (NCT03969121) are going to be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) under the following title:

(P5-09-01) Neoadjuvant hormonal therapy plus palbociclib versus hormonal therapy plus placebo in women with operable, hormone sensitive and HER2-negative primary breast cancer

[link will be provided when the SABCS meeting resources are made available to the public]

Based on a separate protocol, translational research is ongoing to analyze the molecular changes by treatments.

[Collaborator's Work] Ribociclib plus Endocrine Therapy in MONALEESA-7: Updated OS Data

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

by Yen-Shen Lu, Seock Ah-Im, Louis Chow, and colleagues

Click the link below to read more:

https://aacrjournals.org/clincancerres/article/28/5/851/681697/Updated-Overall-Survival-of-Ribociclib-plus

[Collaborator's Work] Intratumoral and Stromal CD4+ T Cell Density as Predictor of pCR in TNBC

Immune Microenvironment, Homologous Recombination Deficiency, and Therapeutic Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

by Takayuki Ueno, Shinji Ohno, Masakazu Toi, and colleagues

Click the link below to read more:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036790/